井平 圭 (イヒラ ケイ)

北海道大学病院 小児・周産・女性科助教

研究者基本情報

■ 学位
  • PhD, 北海道大学
■ URL
researchmap URLホームページURL■ ID 各種
J-Global ID■ 研究キーワード・分野
研究分野
  • ライフサイエンス, 産婦人科学
■ 担当教育組織

研究活動情報

■ 論文
  • cfDNA-inferred putative clonal hematopoiesis during first-line platinum-to-PARP inhibitor maintenance in ovarian cancer.
    Mika Okazawa-Sakai; Takao Fujisawa; Tatsuyuki Chiyoda; Hiroshi Yagi; Ichinosuke Hyodo; Shogen Boku; Yoh Hayasaki; Masanori Isobe; Daisuke Shintani; Kosei Hasegawa; Tomomi Egawa-Takata; Kimihiko Ito; Kei Ihira; Hidemichi Watari; Kazuhiro Takehara; Kiyoko Kato; Hiromichi Nakajima; Kenichi Harano; Yoshiaki Nakamura; Hideaki Bando; Takayuki Yoshino; Daisuke Aoki
    Journal of gynecologic oncology, 2026年07月27日, [国際誌]
    英語, 研究論文(学術雑誌), OBJECTIVE: To describe cell-free DNA (cfDNA)-inferred putative clonal hematopoiesis (CH) candidates during first-line platinum-based chemotherapy followed by poly(ADP-ribose) polymerase inhibitor (PARPi) maintenance in ovarian cancer. METHODS: In SCRUM-Japan MONSTAR-SCREEN-1, we analyzed clinically reported paired tumor tissue and plasma cfDNA profiling (324-gene assays). Baseline (B1) data were assessed in 35 treatment-naïve patients; longitudinal cfDNA was available at B1, after platinum without progression (B2), and during/after PARPi without progression (B3) in 8 patients. Putative CH candidates were defined as pathogenic variants (variant allele frequency <40%) in prespecified CH-related genes detected in plasma but not detected in matched tumor tissue at clinical reporting thresholds. RESULTS: At B1, putative CH candidates were reported in 19/35 patients (54.3%), most commonly DNMT3A; positivity was associated with age ≥60 years. In the longitudinal cohort, tumor-derived TP53 variants were below the assay reporting threshold at B3 in all patients, whereas putative CH TP53 variants were reported in 0/8 patients at B1 and 6/8 patients at B3. DNA damage response gene candidates (TP53/ATM/CHEK2) more frequently became detectable above the reporting threshold during B2-B3 than during B1-B2, while epigenetic-gene candidates showed relatively stable detectability. No therapy-related myeloid neoplasm events were observed during follow-up. CONCLUSION: This paired tissue-plasma longitudinal analysis highlights an interpretive challenge in cfDNA testing during first-line platinum-to-PARPi maintenance therapy: putative CH candidates may become detectable as tumor-derived cfDNA declines. Given cfDNA-only inference without matched WBC sequencing and the small serial cohort, these observations are supportive of prior reports of CH dynamics but require validation in larger WBC-integrated cohorts. TRIAL REGISTRATION: UMIN-CTR Clinical Trial Identifier: UMIN000036749.
  • Gut microbiome associated with PARP inhibitor efficacy in patients with ovarian cancer
    Mika Okazawa-Sakai; Shunsuke A. Sakai; Ichinosuke Hyodo; Satoshi Horasawa; Kentaro Sawada; Takao Fujisawa; Yasuko Yamamoto; Shogen Boku; Yoh Hayasaki; Masanori Isobe; Daisuke Shintani; Kosei Hasegawa; Tomomi Egawa-Takata; Kimihiko Ito; Kei Ihira; Hidemichi Watari; Kazuhiro Takehara; Hiroshi Yagi; Kiyoko Kato; Tatsuyuki Chiyoda; Kenichi Harano; Yoshiaki Nakamura; Riu Yamashita; Takayuki Yoshino; Daisuke Aoki
    Journal of Gynecologic Oncology, 36, XMLink, 2025年, [査読有り]
    研究論文(学術雑誌)
  • Integrated multi-omics analyses and functional validation reveal TTK as a novel EMT activator for endometrial cancer
    Yu Miao; Yosuke Konno; Baojin Wang; Lin Zhu; Tianyue Zhai; Kei Ihira; Noriko Kobayashi; Hidemichi Watari; Xin Jin; Junming Yue; Peixin Dong; Mingyan Fang
    Journal of Translational Medicine, 21, 1, Springer Science and Business Media {LLC}, 2023年02月25日, [査読有り]
    英語, 研究論文(学術雑誌), Abstract
    Background
    Cancer-testis antigens (CTAs) are often expressed in tumor and testicular tissues but not in other normal tissues. To date, there has been no comprehensive study of the expression and clinical significance of CTA genes associated with endometrial cancer (EC) development. Additionally, the clinical relevance, biological role, and molecular mechanisms of the CTA gene TTK protein kinase (TTK) in EC are yet to be fully understood.

    Methods
    Using bioinformatics methods, we comprehensively investigated the genomic, transcriptomic, and epigenetic changes associated with aberrant TTK overexpression in EC samples from the TCGA database. We further investigated the mechanisms of the lower survival associated with TTK dysregulation using single-cell data of EC samples from the GEO database. Cell functional assays were used to confirm the biological roles of TTK in EC cells.

    Results
    We identified 80 CTA genes that were more abundant in EC than in normal tissues, and high expression of TTK was significantly linked with lower survival in EC patients. Furthermore, ROC analysis revealed that TTK could accurately distinguish stage I EC tissues from benign endometrial samples, suggesting that TTK has the potential to be a biomarker for early EC detection. We found TTK overexpression was more prevalent in EC patients with high-grade, advanced tumors, serous carcinoma, and TP53 alterations. Furthermore, in EC tissue, TTK expression showed a strong positive correlation with EMT-related genes. With single-cell transcriptome data, we identified a proliferative cell subpopulation with high expression of TTK and known epithelial–mesenchymal transition (EMT)-related genes and transcription factors. When proliferative cells were grouped according to TTK expression levels, the overexpressed genes in the TTKhigh group were shown to be functionally involved in the control of chemoresistance. Utilizing shRNA to repress TTK expression in EC cells resulted in substantial decreases in cell proliferation, invasion, EMT, and chemoresistance. Further research identified microRNA-21 (miR-21) as a key downstream regulator of TTK-induced EMT and chemoresistance. Finally, the TTK inhibitor AZ3146 was effective in reducing EC cell growth and invasion and enhancing the apoptosis of EC cells generated by paclitaxel.

    Conclusion
    Our findings establish the clinical significance of TTK as a new biomarker for EC and an as-yet-unknown carcinogenic function. This present study proposes that the therapeutic targeting of TTK might provide a viable approach for the treatment of EC.
  • Patterns and predictors of site‐specific recurrence in cervical cancer after radical hysterectomy
    Tatsuya Kato; Chisa Shimada; Fumi Kato; Hiromi Okada‐Kanno; Mahito Takeda; Daisuke Endo; Kei Ihira; Takashi Mitamura; Yosuke Konno; Noriaki Sakuragi; Hidemichi Watari
    Journal of Obstetrics and Gynaecology Research, Wiley, 2022年09月29日
    研究論文(学術雑誌)
  • Long Non-Coding RNA TMPO-AS1 Promotes GLUT1-Mediated Glycolysis and Paclitaxel Resistance in Endometrial Cancer Cells by Interacting With miR-140 and miR-143.
    Peixin Dong; Feng Wang; Mohammad Taheri; Ying Xiong; Kei Ihira; Noriko Kobayashi; Yosuke Konno; Junming Yue; Hidemichi Watari
    Frontiers in oncology, 12, 912935, 912935, 2022年, [国際誌]
    英語, 研究論文(学術雑誌), Increased glycolysis in tumor cells is frequently associated with drug resistance. Overexpression of glucose transporter-1 (GLUT1) promotes the Warburg effect and mediates chemoresistance in various cancers. Aberrant GLUT1 expression is considered as an essential early step in the development of endometrial cancer (EC). However, its role in EC glycolysis and chemoresistance and the upstream mechanisms underlying GLUT1 overexpression, remain undefined. Here, we demonstrated that GLUT1 was highly expressed in EC tissues and cell lines and that high GLUT1 expression was associated with poor prognosis in EC patients. Both gain-of-function and loss-of-function studies showed that GLUT1 increased EC cell proliferation, invasion, and glycolysis, while also making them resistant to paclitaxel. The long non-coding RNA TMPO-AS1 was found to be overexpressed in EC tissues and to be negatively associated with EC patient outcomes. RNA-immunoprecipitation and luciferase reporter assays confirmed that TMPO-AS1 elevated GLUT1 expression by directly binding to two critical tumor suppressor microRNAs (miR-140 and miR-143). Downregulation of TMPO-AS1 remarkably reduced EC cell proliferation, invasion, glycolysis, and paclitaxel resistance in EC cells. This study established that dysregulation of the TMPO-AS1-miR-140/miR-143 axis contributes to glycolysis and drug resistance in EC cells by up-regulating GLUT1 expression. Thus, inhibiting TMPO-AS1 and GLUT1 may prove beneficial in overcoming glycolysis-induced paclitaxel resistance in patients with EC.
  • Long non-coding RNA DLEU2 drives EMT and glycolysis in endometrial cancer through HK2 by competitively binding with miR-455 and by modulating the EZH2/miR-181a pathway
    Peixin Dong; Ying Xiong; Yosuke Konno; Kei Ihira; Noriko Kobayashi; Junming Yue; Hidemichi Watari
    Journal of Experimental & Clinical Cancer Research, 40, 1, Springer Science and Business Media LLC, 2021年12月
    研究論文(学術雑誌), Abstract
    Background
    Epithelial-to-mesenchymal transition (EMT) and aerobic glycolysis are fundamental processes implicated in cancer metastasis. Although increasing evidence demonstrates an association between EMT induction and enhanced aerobic glycolysis in human cancer, the mechanisms linking these two conditions in endometrial cancer (EC) cells remain poorly defined.



    Methods
    We characterized the role and molecular mechanism of the glycolytic enzyme hexokinase 2 (HK2) in mediating EMT and glycolysis and investigated how long noncoding RNA DLEU2 contributes to the stimulation of EMT and glycolysis via upregulation of HK2 expression.



    Results
    HK2 was highly expressed in EC tissues, and its expression was associated with poor overall survival. Overexpression of HK2 effectively promoted EMT phenotypes and enhanced aerobic glycolysis in EC cells via activating FAK and its downstream ERK1/2 signaling. Moreover, microRNA-455 (miR-455) served as a tumor suppressor by directly interacting with HK2 mRNA and inhibiting its expression. Furthermore, DLEU2 displayed a significantly higher expression in EC tissues, and increased DLEU2 expression was correlated with worse overall survival. DLEU2 acted as an upstream activator for HK2-induced EMT and glycolysis in EC cells through two distinct mechanisms: (i) DLEU2 induced HK2 expression by competitively binding with miR-455, and (ii) DLEU2 also interacted with EZH2 to silence a direct inhibitor of HK2, miR-181a.



    Conclusions
    This study identified DLEU2 as an upstream activator of HK2-driven EMT and glycolysis in EC cells and provided significant mechanistic insights for the potential treatment of EC.


  • The difficulty to diagnose cervical cancer developing in the perinatal period with the first‐trimester cytology: A retrospective study
    Hiroyuki Yamazaki; Takashi Mitamura; Kei Ihira; Daisuke Endo; Manami Sakurai; Yosuke Konno; Hidemichi Watari
    Journal of Obstetrics and Gynaecology Research, 47, 9, 3303, 3309, Wiley, 2021年09月
    研究論文(学術雑誌)
  • Critical Roles of PIWIL1 in Human Tumors: Expression, Functions, Mechanisms, and Potential Clinical Implications
    Peixin Dong; Ying Xiong; Yosuke Konno; Kei Ihira; Daozhi Xu; Noriko Kobayashi; Junming Yue; Hidemichi Watari
    Frontiers in Cell and Developmental Biology, 9, Frontiers Media SA, 2021年02月26日
    研究論文(学術雑誌), P-element-induced wimpy testis (PIWI)-interacting RNAs (piRNAs) are a class of small non-coding RNA molecules that are 24–31 nucleotides in length. PiRNAs are thought to bind to PIWI proteins (PIWL1-4, a subfamily of Argonaute proteins), forming piRNA/PIWI complexes that influence gene expression at the transcriptional or post-transcriptional levels. However, it has been recently reported that the interaction of PIWI proteins with piRNAs does not encompass the entire function of PIWI proteins in human tumor cells. PIWIL1 (also called HIWI) is specifically expressed in the testis but not in other normal tissues. In tumor tissues, PIWIL1 is frequently overexpressed in tumor tissues compared with normal tissues. Its high expression is closely correlated with adverse clinicopathological features and shorter patient survival. Upregulation of PIWIL1 drastically induces tumor cell proliferation, epithelial-mesenchymal transition (EMT), invasion, cancer stem-like properties, tumorigenesis, metastasis and chemoresistance, probably via piRNA-independent mechanisms. In this article, we summarize the current existing literature on PIWIL1 in human tumors, including its expression, biological functions and regulatory mechanisms, providing new insights into how the dysregulation of PIWIL1 contributes to tumor initiation, development and chemoresistance through diverse signaling pathways. We also discuss the most recent findings on the potential clinical applications of PIWIL1 in cancer diagnosis and treatment.
  • PD-L1 Is a Tumor Suppressor in Aggressive Endometrial Cancer Cells and Its Expression Is Regulated by miR-216a and lncRNA MEG3
    Daozhi Xu; Peixin Dong; Ying Xiong; Rui Chen; Yosuke Konno; Kei Ihira; Junming Yue; Hidemichi Watari
    Frontiers in Cell and Developmental Biology, 8, Frontiers Media SA, 2020年12月09日
    研究論文(学術雑誌), BackgroundPoorly differentiated endometrioid adenocarcinoma and serous adenocarcinoma represent an aggressive subtype of endometrial cancer (EC). Programmed death-ligand-1 (PD-L1) was known to exhibit a tumor cell-intrinsic function in mediating immune-independent tumor progression. However, the functional relevance of tumor cell-intrinsic PD-L1 expression in aggressive EC cells and the mechanisms regulating its expression remain unknown.

    MethodsPD-L1 expression in 65 EC tissues and 18 normal endometrium samples was analyzed using immunohistochemical staining. The effects of PD-L1 on aggressive EC cell growth, migration and invasion were investigated by cell functional assays. Luciferase reporter assays were used to reveal the microRNA-216a (miR-216a)-dependent mechanism modulating the expression of PD-L1.

    ResultsPositive PD-L1 expression was identified in 84% of benign cases but only in 12% of the EC samples, and the staining levels of PD-L1 in EC tissues were significantly lower than those in the normal tissues. Higher PD-L1 expression predicts favorable survival in EC. Ectopic expression of PD-L1 in aggressive EC cells results in decreased cell proliferation and the loss of mesenchymal phenotypes. Mechanistically, PD-L1 exerts the anti-tumor effects by downregulating MCL-1 expression. We found that PD-L1 levels in aggressive EC cells are regulated by miR-216a, which directly targets PD-L1. We further identified a mechanism whereby the long non-coding RNA MEG3 represses the expression of miR-216a, thereby leading to increased PD-L1 expression and significant inhibition of cell migration and invasion.

    ConclusionThese results reveal an unappreciated tumor cell-intrinsic role for PD-L1 as a tumor suppressor in aggressive EC cells, and identify MEG3 and miR-216a as upstream regulators of PD-L1.

  • Tailored radical hysterectomy for locally advanced cervical cancer.
    Noriaki Sakuragi; Masanori Kaneuchi; Tatsuya Kato; Chisa Shimada; Yukiharu Todo; Kei Ihira; Ayako Nozaki; Takeshi Umazume; Yosuke Konno; Takashi Mitamura; Noriko Kobayashi; Gen Murakami; Hidemichi Watari
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2020年06月09日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), OBJECTIVE: The survival and prognostic factors for locally advanced cervical cancer treated with nerve-sparing Okabayashi-Kobayashi radical hysterectomy have not been elucidated. We aimed to evaluate the oncological outcomes of those patients after radical hysterectomy with adjuvant chemotherapy. METHODS: This retrospective cohort study was conducted from January 2002 to December 2011. Treatment was conducted at a single tertiary center in northern Japan. We used the Okabayashi-Kobayashi radical hysterectomy with lymphadenectomy. We applied unilateral nerve preservation for stage IIA/IIB cancer if there was a one-sided extension of the disease outside the cervix. Indication for adjuvant therapy was based on Sedlis criteria. High-risk was defined as evidence of lymph node metastasis, pathological parametrial invasion, and a positive/close surgical margin. The choice of adjuvant therapy was chemotherapy which consisted of paclitaxel and cisplatin. RESULTS: The study included 76 early-stage IB1 (≤4 cm) and IIA1 cervical cancer and 45 locally advanced stage IB2 (>4 cm), IIA2, and IIB disease treated consecutively. The median follow-up was 106 (range: 6-203) months. There were 18 (15%) patients with recurrence, with five of 76 in the early-stage (7%) and 13 of 45 in the locally advanced disease (29%) (P<0.001). For locally advanced cervical cancer, pT classification (P<0.001), lymph node metastasis (P=0.007), and histology (P=0.05) were associated with locoregional recurrence. The five-year locoregional recurrence rate in the locally advanced disease was 20% and 5% in the early-stage disease (P=0.01). The five-year disease-free survival in the locally advanced cervical cancer was 71% and 93% in the early-stage disease (P<0.001). The overall survival in locally advanced disease depended on the adeno-type histology and lymph node metastasis. CONCLUSION: The tailored use of nerve-sparing Okabayashi-Kobayashi radical hysterectomy with adjuvant chemotherapy based on tumor histology and lymph node metastasis may be a possible option as a treatment of locally advanced cervical cancer in selected patients.
  • The Expression, Functions and Mechanisms of Circular RNAs in Gynecological Cancers.
    Dong P; Xu D; Xiong Y; Yue J; Ihira K; Konno Y; Watari H
    Cancers, 2020年06月, [査読有り]
    研究論文(学術雑誌)
  • Four versus six chemotherapy cycles in endometrial carcinoma with a high risk of recurrence: a retrospective study.
    Michinori Mayama; Hiroshi Asano; Eiji Nomura; Kei Ihira; Ayako Nozaki; Tatsuya Kato; Yousuke Konno; Takashi Mitamura; Noriko Kobayashi; Mahito Takeda; Masataka Kudo; Hidemichi Watari
    Japanese journal of clinical oncology, 2020年04月23日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), OBJECTIVE: This study compared the survival outcomes and the incidence of chemotherapy-related adverse events in endometrial cancer patients who received four and six cycles of adjuvant chemotherapy to examine the optimal number of adjuvant chemotherapy cycles. METHODS: A total of 112 patients with endometrial cancer with a high risk of recurrence were retrospectively enrolled; 46 patients received four cycles and 66 received six cycles of adjuvant chemotherapy. Between-group differences of overall survival, disease-free survival, hematological and non-hematological toxicities were analyzed. Baseline patient's background differences were assessed with inverse probability of treatment weighting using propensity score. RESULTS: Overall and disease-free survivals between the two groups were not significantly different. Paclitaxel + carboplatin, every 3-4 weeks was the most frequently used chemotherapy regimen in both groups. Patients in the six-cycle chemotherapy group developed neutropenia G4 or febrile neutropenia more frequently than those in the four-cycle group; odds ratio (95% confidence interval) is 4.07 (1.51-10.96). Peripheral sensory neuropathy was the most frequently observed non-hematological toxicity; the incidence of peripheral sensory neuropathy was not significantly different between four- and six-cycle chemotherapy group, P = 0.832. The result was same in the subgroup analysis in patients who received TC regimen, P = 0.455. CONCLUSION: This study implies a possible benefit of fewer cycles of adjuvant chemotherapy in endometrial cancer patients with a high risk of recurrence because of the lower incidence of hematological toxicities without impairing survival outcomes.
  • MicroRNA-361-Mediated Inhibition of HSP90 Expression and EMT in Cervical Cancer Is Counteracted by Oncogenic lncRNA NEAT1
    daozhi Xu; Peixin Dong; Ying Xiong; Junming Yue; Yosuke Konno; Kei Ihira; Noriko Kobayashi; Yukiharu Todo; Hidemichi Watari
    Cells, 9, 3, 632, 632, {MDPI} {AG}, 2020年03月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • L1CAM Predicts Adverse Outcomes in Patients with Endometrial Cancer Undergoing Full Lymphadenectomy and Adjuvant Chemotherapy.
    Hiroshi Asano; Kanako C Hatanaka; Ryosuke Matsuoka; Peixin Dong; Takashi Mitamura; Yosuke Konno; Tatsuya Kato; Noriko Kobayashi; Kei Ihira; Ayako Nozaki; Akira Oku; Yoshihiro Matsuno; Yutaka Hatanaka; Hidemichi Watari
    Annals of surgical oncology, 2019年12月02日, [査読有り], [国際誌]
    英語, BACKGROUND: L1 cell adhesion molecule (L1CAM) has been established as an important predictor of poor survival of early-stage endometrial cancer patients. We investigated whether L1CAM remains a significant predictor of poor survival of patients with advanced-stage endometrial cancer undergoing extensive surgical staging and adjuvant chemotherapy. METHODS: We prepared tissue microarray (TMA) from surgical tissue specimens of 161 endometrial cancer patients who underwent full lymphadenectomy combined with adjuvant chemotherapy for patients at risk for recurrence, and evaluated expression of L1CAM using immunohistochemistry. The correlation between L1CAM positivity and clinicopathological factors and the prognostic significance of L1CAM expression was investigated. RESULTS: Among 161 cases who had a follow-up duration of over 3 years, 48 cases (29.8%) showed positive staining for L1CAM. L1CAM positivity was significantly correlated with non-endometrioid histology (p < 0.0001), vascular invasion (p = 0.0157), and positive cytology (p = 0.005), and was a significant predictor of poor survival among advanced-stage patients, but not early-stage patients in our cohort. L1CAM-positive patients showed a higher recurrence rate and frequency of distant failure than L1CAM-negative patients. Multivariate analysis revealed that para-aortic lymph node metastasis (PANM) and L1CAM positivity were independent predictors of poor survival. Overall survival can be stratified into three groups by the combination of PANM and L1CAM positivity. CONCLUSION: L1CAM is an independent predictor of poor survival in endometrial cancer patients undergoing full lymphadenectomy and adjuvant chemotherapy, thus indicating that L1CAM can be clinically used as a biomarker to identify those patients at increased risk of recurrence.
  • MicroRNA-361: A Multifaceted Player Regulating Tumor Aggressiveness and Tumor Microenvironment Formation.
    Xu D; Dong P; Xiong Y; Yue J; Ihira K; Konno Y; Kobayashi N; Todo Y; Watari H
    Cancers, 2019年08月, [査読有り]
    研究論文(学術雑誌)
  • Long noncoding RNA NEAT1 drives aggressive endometrial cancer progression via miR-361-regulated networks involving STAT3 and tumor microenvironment-related genes.
    Dong P; Xiong Y; Yue J; Xu D; Ihira K; Konno Y; Kobayashi N; Todo Y; Watari H
    Journal of experimental & clinical cancer research : CR, 2019年07月, [査読有り]
    研究論文(学術雑誌)
  • 北海道のリンパ浮腫診療の現状と課題
    小林 範子; 藤野 敬史; 野崎 綾子; 小林 由佳子; 井平 圭; 朝野 拓史; 三田村 卓; 金野 陽輔; 加藤 達矢; 武田 真人; 和田 真一郎; 櫻木 範明; 渡利 英道
    日本リンパ浮腫治療学会雑誌, 2, 1, 44, 47, (一社)日本リンパ浮腫治療学会, 2019年05月, [査読有り]
    日本語
  • 悪性腹膜中皮腫の1例
    奥 聡; 武田 真人; 朝野 拓史; 小林 由佳子; 井平 圭; 野崎 綾子; 金野 陽輔; 加藤 達矢; 工藤 正尊; 渡利 英道; 清水 亜衣; 松野 吉宏
    北海道産科婦人科学会会誌, 63, 1, 64, 64, 北海道産科婦人科学会, 2019年03月
    日本語
  • Molecular-targeted therapies and precision medicine for endometrial cancer.
    Mitamura T; Dong P; Ihira K; Kudo M; Watari H
    Japanese journal of clinical oncology, 2018年11月, [査読有り]
  • EZH2 inhibition suppresses endometrial cancer progression via miR-361/Twist axis
    Kei Ihira; Peixin Dong; Ying Xiong; Hidemichi Watari; Yosuke Konno; Sharon J. B. Hanley; Masayuki Noguchi; Noriyuki Hirata; Futoshi Suizu; Takahiro Yamada; Masataka Kudo; Noriaki Sakuragi
    ONCOTARGET, 8, 8, 13509, 13520, 2017年02月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Suppression of iASPP-dependent aggressiveness in cervical cancer through reversal of methylation silencing of microRNA-124
    Peixin Dong; Ying Xiong; Hidemichi Watari; Sharon J. B. Hanley; Yosuke Konno; Kei Ihira; Fumihiko Suzuki; Takahiro Yamada; Masataka Kudo; Junming Yue; Noriaki Sakuragi
    SCIENTIFIC REPORTS, 6, 35480, 2016年10月, [査読有り]
    英語, 研究論文(学術雑誌)
  • MiR-137 and miR-34a directly target Snail and inhibit EMT, invasion and sphere-forming ability of ovarian cancer cells.
    Dong P; Xiong Y; Watari H; Hanley SJ; Konno Y; Ihira K; Yamada T; Kudo M; Yue J; Sakuragi N
    Journal of experimental & clinical cancer research : CR, 35, 1, 132, 2016年09月, [査読有り]
  • MiR-137 and miR-34a directly target Snail and inhibit EMT, invasion and sphere-forming ability of ovarian cancer cells
    Peixin Dong; Ying Xiong; Hidemichi Watari; Sharon J. B. Hanley; Yosuke Konno; Kei Ihira; Takahiro Yamada; Masataka Kudo; Junming Yue; Noriaki Sakuragi
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 35, 2016年09月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Reactivation of epigenetically silenced miR-124 reverses the epithelial-to-mesenchymal transition and inhibits invasion in endometrial cancer cells via the direct repression of IQGAP1 expression
    Peixin Dong; Kei Ihira; Ying Xiong; Hidemichi Watari; Sharon J. B. Hanley; Takahiro Yamada; Masayoshi Hosaka; Masataka Kudo; Junming Yue; Noriaki Sakuragi
    ONCOTARGET, 7, 15, 20260, 20270, 2016年04月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Reactivating p53 functions by suppressing its novel inhibitor iASPP: a potential therapeutic opportunity in p53 wild-type tumors
    Peixin Dong; Kei Ihira; Junichi Hamada; Hidemichi Watari; Takahiro Yamada; Masayoshi Hosaka; Sharon J. B. Hanley; Masataka Kudo; Noriaki Sakuragi
    ONCOTARGET, 6, 24, 19968, 19975, 2015年08月, [査読有り]
    英語, 研究論文(学術雑誌)
■ その他活動・業績
  • 卵巣癌希少組織型患者由来ゼノグラフトモデルを用いたニラパリブの抗腫瘍効果の検討
    黒須博之; 朝野拓史; 山本竜太郎; 山崎博之; 良川大晃; 井平圭; 遠藤大介; 三田村卓; 金野陽輔; 加藤達矢; 小林範子; 渡利英道, 日本産科婦人科学会雑誌, 74, 2022年
  • 多発肝転移を伴うS状結腸原発非妊娠性絨毛癌の1例
    井平圭; 山崎博之; 朝野拓史; 遠藤大介; 三田村卓; 金野陽輔; 加藤達矢; 渡利英道; 清水亜衣; 松野吉宏, 日本婦人科腫瘍学会学術講演会プログラム・抄録集(Web), 63rd, 2021年
  • L1CAMはsurgical stagingを受けた進行子宮体癌症例の独立予後不良因子である
    奥 聡; 朝野 拓史; 畑中 佳奈子; 松岡 亮介; 加藤 達矢; 金野 陽輔; 三田村 卓; 井平 圭; 野崎 綾子; 武田 真人; 小林 範子; 工藤 正尊; 松野 吉宏; 畑中 豊; 渡利 英道, 北日本産科婦人科学会総会・学術講演会プログラム・抄録集, 67回, 49, 49, 2019年09月
    東北連合産科婦人科学会・北日本産科婦人科学会, 日本語
  • リンパ節転移低リスクの子宮体癌に対するリンパ節郭清省略の妥当性についての検討
    朝野 拓史; 小林 由佳子; 野崎 綾子; 井平 圭; 三田村 卓; 金野 陽輔; 加藤 達矢; 小林 範子; 武田 真人; 工藤 正尊; 渡利 英道, 産婦人科手術, 30, 167, 167, 2019年08月, [査読有り]
    (株)メジカルビュー社, 日本語
  • L1CAM陽性子宮体癌の臨床病理学的検討
    朝野 拓史; 畑中 佳奈子; 松岡 亮介; 小林 由佳子; 井平 圭; 野崎 綾子; 三田村 卓; 金野 陽輔; 加藤 達矢; 武田 真人; 小林 範子; 工藤 正尊; 畑中 豊; 松野 吉宏; 渡利 英道, 日本婦人科腫瘍学会雑誌, 37, 3, 499, 499, 2019年06月
    (公社)日本婦人科腫瘍学会, 日本語
  • 【妊婦の腫瘍性疾患の管理-見つけたらどう対応するか】悪性疾患 妊婦に対する子宮頸部円錐切除術の適応
    井平 圭; 森川 守; 渡利 英道, 臨床婦人科産科, 73, 5, 463, 467, 2019年05月
    (株)医学書院, 日本語
  • 悪性腹膜中皮腫の1例
    奥 聡; 武田 真人; 朝野 拓史; 小林 由佳子; 井平 圭; 野崎 綾子; 金野 陽輔; 加藤 達矢; 工藤 正尊; 渡利 英道; 清水 亜衣; 松野 吉宏, 北日本産科婦人科学会総会・学術講演会プログラム・抄録集, 65回, 134, 134, 2017年09月
    東北連合産科婦人科学会・北日本産科婦人科学会, 日本語
  • MRIによる子宮体癌と子宮癌肉腫の鑑別に関する検討
    常田 慧徳; 加藤 扶美; 朝野 拓史; 野崎 綾子; 井平 圭; 三田村 卓; 金野 陽輔; 加藤 達矢; 渡利 英道; 飯嶋 由紀; 西岡 井子; 真鍋 徳子; 工藤 與亮, 日本医学放射線学会秋季臨床大会抄録集, 53回, S470, S471, 2017年08月
    (公社)日本医学放射線学会, 日本語
  • 当科におけるロボット支援腹腔鏡下子宮悪性腫瘍手術の初期導入成績について
    加藤 達矢; 工藤 正尊; 朝野 拓史; 嶋田 知紗; 野崎 綾子; 井平 圭; 金野 陽輔; 保坂 昌芳; 渡利 英道; 櫻木 範明, 産婦人科手術, 28, 156, 156, 2017年06月
    (株)メジカルビュー社, 日本語
  • 子宮頸部円錐切除術前後におけるHPVタイピング検査の有用性の検討
    金野 陽輔; 朝野 拓史; 嶋田 知紗; 井平 圭; 加藤 達矢; 小林 範子; 武田 真人; 渡利 英道; 工藤 正尊; 櫻木 範明, 日本婦人科腫瘍学会雑誌, 35, 3, 525, 525, 2017年06月
    (公社)日本婦人科腫瘍学会, 日本語
  • 腹水貯留原発不明癌の診断確定に腹水セルブロックが有用であった一例
    井平 圭; 朝野 拓史; 嶋田 知紗; 野崎 綾子; 遠藤 大介; 金野 陽輔; 加藤 達矢; 武田 真人; 渡利 英道; 櫻木 範明, 日本婦人科腫瘍学会雑誌, 35, 3, 615, 615, 2017年06月
    (公社)日本婦人科腫瘍学会, 日本語
  • 化学療法耐性卵巣癌に対するEZH2阻害剤とpaclitaxelの相乗効果に関する検討
    遠藤 大介; 渡利 英道; 朝野 拓史; 嶋田 知紗; 井平 圭; 宇田 智浩; 金野 陽輔; 加藤 達矢; 小林 範子; 武田 真人; 工藤 正尊; 櫻木 範明, 日本婦人科腫瘍学会雑誌, 35, 3, 633, 633, 2017年06月
    (公社)日本婦人科腫瘍学会, 日本語
  • 明細胞性卵巣癌におけるEZH2、ARID1Aの発現と予後についての検討
    野崎 綾子; 渡利 英道; 朝野 拓史; 小林 由佳子; 嶋田 知紗; 井平 圭; 遠藤 大介; 金野 陽輔; 加藤 達矢; 武田 真人; 工藤 正尊; 櫻木 範明, 日本婦人科腫瘍学会雑誌, 35, 3, 642, 642, 2017年06月
    (公社)日本婦人科腫瘍学会, 日本語
  • 高悪性度子宮体癌と比較した子宮体部癌肉腫症例の臨床病理学的特徴について
    嶋田 知紗; 渡利 英道; 加藤 達矢; 野崎 綾子; 小林 由佳子; 朝野 拓史; 井平 圭; 金野 陽輔; 小林 範子; 武田 真人; 工藤 正尊; 櫻木 範明, 日本婦人科腫瘍学会雑誌, 35, 3, 671, 671, 2017年06月
    (公社)日本婦人科腫瘍学会, 日本語
  • 腟式細切により子宮を回収した電動モルセレーターを使用しないTLH後に発生した異所性子宮筋腫の1例
    石塚 泰也; 工藤 正尊; 大原 康弘; 山崎 博之; 井平 圭; 宇田 智浩; 中谷 真紀子; 加藤 達矢; 渡利 英道; 櫻木 範明, 日本産科婦人科内視鏡学会雑誌, 33, 1, 131, 137, 2017年04月
    46歳(1経妊1経産)。子宮平滑筋腫に対する電動セルモーターを使用しない腹腔鏡下子宮全摘出術後59ヵ月目の定期検診にて腟断端右端の腫瘤影を指摘された。各種検査結果と手術歴から異所性子宮筋腫(PM)を第一に疑い、審査腹腔鏡となった。腹腔鏡所見では腟断端右端に相当する部位に後腹膜腔内に発育する6cm大の腫瘤性病変を認めたが、腸管との連続性はなかった。また、腟断端左側に同様の腫瘤が2個認められた。1個の腫瘤を摘出し、病理組織学的にPMと診断されたため、後日、腹腔鏡下に残りの腫瘤を摘出した。最終手術から1年経過現在、再発はみられていない。, (一社)日本産科婦人科内視鏡学会, 日本語
  • 卵巣癌において化学療法後のオートタキシンの高発現は予後不良因子である
    金野 陽輔; 遠藤 大介; 朝野 拓史; 嶋田 知紗; 野崎 綾子; 井平 圭; 加藤 達矢; 小林 範子; 武田 真人; 渡利 英道; 工藤 正尊; 櫻木 範明, 日本産科婦人科学会雑誌, 69, 2, 686, 686, 2017年02月
    (公社)日本産科婦人科学会, 日本語
  • 卵巣明細胞性腺癌におけるEZH2、ARID1Aの発現と予後についての検討
    野崎 綾子; 渡利 英道; 朝野 拓史; 小林 由佳子; 嶋田 知紗; 井平 圭; 遠藤 大介; 金野 陽輔; 加藤 達矢; 武田 真人; 工藤 正尊; 櫻木 範明, 日本産科婦人科学会雑誌, 69, 2, 687, 687, 2017年02月
    (公社)日本産科婦人科学会, 日本語
  • シスプラチン/パクリタキセル併用化学療法を受ける子宮頸癌・体癌患者における嘔気・嘔吐に対する標準制吐療法と六君子湯併用制吐療法の第II相比較試験(JORTC-KMP02)
    嶋田 知紗; 渡利 英道; 大場 洋子; 山口 正博; 勘野 真紀; 朝野 拓史; 井平 圭; 野崎 綾子; 金野 陽輔; 加藤 達矢; 野村 英司; 櫻木 範明, 日本産科婦人科学会雑誌, 69, 2, 922, 922, 2017年02月
    (公社)日本産科婦人科学会, 日本語
  • Clinical Efficacy of Paclitaxel/Cisplatin as an Adjuvant Chemotherapy for Patients With Cervical Cancer Who Underwent Radical Hysterectomy and Systematic Lymphadenectomy
    C. Shimada; T. Kato; H. Watari; H. Asano; K. Ihira; D. Endo; A. Nozaki; Y. Konno; M. Takeda; M. Kudo; M. Hisanori; N. Sakuragi, INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 26, 461, 461, 2016年10月
    英語, 研究発表ペーパー・要旨(国際会議)
  • 類内膜癌G3および特殊組織型子宮体癌と比較した子宮体部癌肉腫症例の臨床病理学的特徴について
    朝野 拓史; 渡利 英道; 加藤 達矢; 野崎 綾子; 小林 由佳子; 嶋田 知紗; 井平 圭; 金野 陽輔; 小林 範子; 武田 真人; 工藤 正尊; 櫻木 範明, 北日本産科婦人科学会総会・学術講演会プログラム・抄録集, 64回, 92, 92, 2016年09月
    東北連合産科婦人科学会・北日本産科婦人科学会, 日本語
  • 子宮頸癌に対する広汎子宮全摘術後の補助化学療法の有用性についての後方視的検討
    嶋田 知紗; 加藤 達矢; 朝野 拓史; 山崎 博之; 井平 圭; 遠藤 大介; 福本 俊; 宇田 智浩; 中谷 真紀子; 古田 祐; 三田村 卓; 金野 陽輔; 武田 真人; 小林 範子; 工藤 正尊; 渡利 英道; 櫻木 範明, 日本婦人科腫瘍学会雑誌, 34, 3, 434, 434, 2016年06月
    (公社)日本婦人科腫瘍学会, 日本語
  • 子宮頸癌に対する広汎子宮全摘術後の補助化学療法の有用性についての後方視的検討
    嶋田 知紗; 加藤 達矢; 渡利 英道; 福本 俊; 遠藤 大介; 井平 圭; 古田 祐; 金野 陽輔; 小林 範子; 武田 真人; 櫻木 範明, 日本産科婦人科学会雑誌, 68, 2, 699, 699, 2016年02月
    (公社)日本産科婦人科学会, 日本語
  • ISP-11-6 EZH2 stimulates Twist expression by epigenetic silencing of its suppressor miR-361 through an YY1-dependent mechanism(Group 11 Oncology 3,International Session Poster) :
    Ihira Kei; Dong Peixin; Mitamura Takashi; Konno Yosuke; Kato Tatsuya; Kobayashi Noriko; Takeda Mahito; Watari Hidemichi; Kudo Masataka; Minakami Hisanori; Sakuragi Noriaki, 日本産科婦人科學會雜誌, 68, 2, 508, 508, 2016年
    日本産科婦人科学会, 英語
  • 子宮体部平滑筋肉腫の3例
    朝野 拓史; 武田 真人; 丸川 活司; 菅野 宏美; 畑中 佳奈子; 福本 俊; 井平 圭; 加藤 達矢; 保坂 昌芳; 渡利 英道; 櫻木 範明; 松野 吉宏, 北海道臨床細胞学会会報, 24, 53, 56, 2015年10月
    北海道臨床細胞学会, 日本語
  • 子宮体部明細胞腺癌の診断経過についての検討
    井平 圭; 朝野 拓史; 丸川 活司; 石塚 泰也; 岡田 宏美; 遠藤 大介; 三田村 卓; 保坂 昌芳; 武田 真人; 渡利 英道; 佐川 正; 畑中 佳奈子; 松野 吉宏; 櫻木 範明, 日本臨床細胞学会雑誌, 54, Suppl.2, 558, 558, 2015年10月
    (公社)日本臨床細胞学会, 日本語
  • 婦人科分野におけるセルブロックの有用性の検討
    前田 悟郎; 朝野 拓史; 丸川 活司; 石塚 泰也; 井平 圭; 遠藤 大介; 岡田 宏美; 三田村 卓; 保坂 昌芳; 武田 真人; 渡利 英道; 佐川 正; 畑中 佳奈子; 松野 吉宏; 櫻木 範明, 日本臨床細胞学会雑誌, 54, Suppl.2, 562, 562, 2015年10月
    (公社)日本臨床細胞学会, 日本語
  • 子宮頸癌 卵巣癌を合併した子宮体部類内膜腺癌(triple cancer)の1例
    齊藤 良玄; 朝野 拓史; 丸川 活司; 石塚 泰也; 岡田 宏美; 井平 圭; 三田村 卓; 保坂 昌芳; 武田 真人; 遠藤 大介; 渡利 英道; 佐川 正; 櫻木 範明, 日本臨床細胞学会雑誌, 54, Suppl.2, 658, 658, 2015年10月
    (公社)日本臨床細胞学会, 日本語
  • Mayer-Rokitansky-Kuster-Hauser症候群に対する腹腔鏡下のDavydov法造腟術
    保坂 昌芳; 山口 正博; 嶋田 知紗; 福本 俊; 井平 圭; 遠藤 大介; 宇田 智浩; 中谷 真紀子; 金野 陽輔; 加藤 達矢; 小林 範子; 武田 真人; 渡利 英道; 工藤 正尊; 櫻木 範明, 日本生殖医学会雑誌, 60, 3, 198, 198, 2015年07月
    (一社)日本生殖医学会, 日本語
  • Mayer-Rokitansky-Kuster-Hauser症候群に対する腹腔鏡下Davydov法造腟術
    保坂 昌芳; 山口 正博; 前田 悟郎; 嶋田 知紗; 福本 俊; 井平 圭; 宇田 智浩; 北川 真紀子; 三田村 卓; 金野 陽輔; 加藤 達矢; 渡利 英道; 工藤 正尊; 水上 尚典; 櫻木 範明, 産婦人科手術, 26, 198, 198, 2015年06月
    (株)メジカルビュー社, 日本語
  • 子宮頸がん基礎 子宮頸部異形成(CIN)の進展とIMP3、ZFP36発現との関連について
    嶋田 知紗; 保坂 昌芳; 渡利 英道; 山口 正博; 福本 俊; 遠藤 大介; 井平 圭; 金野 陽輔; 加藤 達矢; 工藤 正尊; 櫻木 範明, 日本婦人科腫瘍学会雑誌, 33, 3, 532, 532, 2015年06月
    (公社)日本婦人科腫瘍学会, 日本語
  • Mayer-Rokitansky-Kuster-Hauser症候群に対する腹腔鏡下Davydov法造腟術
    福本 俊; 保坂 昌芳; 嶋田 知紗; 井平 圭; 遠藤 大介; 宇田 智浩; 中谷 真紀子; 木村 敬子; 山口 正博; 金野 陽輔; 加藤 達矢; 工藤 正尊; 武田 真人; 渡利 英道; 櫻木 範明, 日本外科系連合学会誌, 40, 3, 623, 623, 2015年05月
    日本外科系連合学会, 日本語
  • 子宮頸部異形成(CIN)の進展とIMP3、ZFP36発現との関連について
    嶋田 知紗; 保坂 昌芳; 渡利 英道; 山口 正博; 福本 俊; 井平 圭; 遠藤 大介; 金野 陽輔; 加藤 達矢; 藤田 博正; 水上 尚典; 櫻木 範明, 日本産科婦人科学会雑誌, 67, 2, 535, 535, 2015年02月
    (公社)日本産科婦人科学会, 日本語
  • ISP-7-3 MicroRNA-101 attenuates Twist1 expression by induction of its negative regulator miR-361-5p through an EZH2-dependent mechanism(Group 7 Oncology 7,IS Poster,International Session) :
    Dong Peixin; Ihira Kei; Hanley Sharon; Yamada Takahiro; Sakuragi Noriaki, 日本産科婦人科學會雜誌, 67, 2, 1020, 1020, 2015年
    日本産科婦人科学会, 英語
  • 後腹膜腔内発育した傍卵管嚢腫を腹腔鏡下に摘出した3例
    嶋田 知紗; 保坂 昌芳; 前田 悟郎; 山口 正博; 木村 敬子; 井平 圭; 遠藤 大介; 福本 俊; 宇田 智浩; 北川 真紀子; 三田村 卓; 金野 陽輔; 加藤 達矢; 小林 範子; 武田 真人; 渡利 英道; 工藤 正尊; 水上 尚典; 櫻木 範明, 日本産科婦人科内視鏡学会雑誌, 30, Suppl.I, 243, 243, 2014年08月
    (一社)日本産科婦人科内視鏡学会, 日本語
  • Mayer-Rokitansky-Kuster-Hauser症候群に対する腹腔鏡下Davydov法造腟術
    福本 俊; 保坂 昌芳; 前田 悟郎; 山口 正博; 木村 敬子; 嶋田 知紗; 井平 圭; 遠藤 大介; 宇田 智浩; 北川 真紀子; 三田村 卓; 金野 陽輔; 加藤 達矢; 小林 範子; 武田 真人; 渡利 英道; 工藤 正尊; 水上 尚典; 櫻木 範明, 日本産科婦人科内視鏡学会雑誌, 30, Suppl.I, 259, 259, 2014年08月
    (一社)日本産科婦人科内視鏡学会, 日本語
  • 子宮体癌妊孕性温存治療における直角0°硬性子宮鏡を用いたtranscervical cold biopsy
    首藤 聡子; 井平 圭; 宇田 智浩; 金野 陽輔; 小田切 哲二; 三田村 卓; 加藤 達矢; 武田 真人; 渡利 英道; 金内 優典; 工藤 正尊; 櫻木 範明, 産婦人科手術, 25, 197, 197, 2014年05月, [査読有り]
    (株)メジカルビュー社, 日本語
  • 重症子宮内膜症術後に尿管腟瘻を来し、腹腔鏡下膀胱尿管新吻合術を行った1例
    宇田 智浩; 工藤 正尊; 井平 圭; 小田切 哲二; 加藤 達矢; 保坂 昌芳; 西 信也; 渡利 英道; 金内 優典; 櫻木 範明, 日本産科婦人科内視鏡学会雑誌, 28, 1, 286, 286, 2012年08月
    (一社)日本産科婦人科内視鏡学会, 日本語
■ 講演・口頭発表等
  • Bevacizumab in ovarian and uterine cervical cancer treatment : 10 year's experience of a single center in Northern Japan
    井平圭
    The 5th Biennial Meeting of Asian Society of Gynecologic Oncology, 2017年10月30日, 英語, ポスター発表
    [国際会議]
  • EZH2 stimulates Twist expression by epigenetic silencing of its suppressor miR-361 through an YY1-dependent mechanism
    井平圭
    The 4th Biennial Meeting of Asian Society of Gynecologic Oncology, 2015年11月, 英語, ポスター発表
    [国際会議]
■ 主な担当授業
  • 基本医学研究, 2024年, 修士課程, 医学院
  • 基本医学総論, 2024年, 修士課程, 医学院
  • 基盤医学研究, 2024年, 博士後期課程, 医学院
  • 社会医学研究, 2024年, 博士後期課程, 医学院
  • 臨床医学研究, 2024年, 博士後期課程, 医学院
  • 医学総論, 2024年, 博士後期課程, 医学院
  • 医学総論, 2024年, 博士後期課程, 医学院
■ 共同研究・競争的資金等の研究課題
  • 新規免疫チェックポイント分子B7H3経路による子宮体癌転移能獲得の分子基盤解明
    科学研究費助成事業
    2019年04月01日 - 2022年03月31日
    井平 圭; 董 培新
    新規免疫チェックポイント分子B7H3は、癌細胞に対する免疫細胞の攻撃力を弱め、癌細胞悪性形質の獲得にも寄与する。本研究では、独自に樹立した高浸潤性亜株及び癌幹細胞様sphere細胞を用い、体癌細胞悪性形質の獲得におけるB7H3の役割とmiR-199aまた変異型p53によるB7H3発現の制御機構の解明を試みた。研究の結果、CTDSPL及びmiR-199aの発現低下、また変異型p53が、B7H3の高発現を引き起こし、下流のPI3K/AKT及びSTAT3経路を活性化することで、体癌細胞の悪性形質の獲得に寄与することが明らかになり、B7H3が体癌の新しい治療標的となりうることが示唆された。
    日本学術振興会, 基盤研究(C), 北海道大学, 19K09769